FDA panel wants new trial for Genzyme med

More bad news for Genzyme: Its leukemia drug Clolar probably won't get a new indication for adults anytime soon. An FDA advisory panel was less than impressed with the company's data supporting expanded use, and the committee voted 9-3 to urge the agency to require a new, randomized trial.

You see, the data Genzyme submitted with its app didn't compare Clolar with another treatment. "In the absence of a randomized trial, we don't have an evidence-based justification that alternative standard therapy wouldn't be better," said panel member Thomas Fleming, a statistician at the University of Washington in Seattle (as quoted by Reuters).

The company is conducting a study comparing Clolar to an older chemo drug, but those results aren't expected till 2011. And the trial is focused on adults 55 and older, rather than a broader age group. Genzyme said it's too soon to say whether it would launch another comparison study; obviously, the FDA itself has to rule, but it usually goes along with advisory panel recommendations.

As you know, this is just the latest in a series of blows for Genzyme, which has been fighting to get a Boston-area plant back on line after it was contaminated by a virus. The plant produces Genzyme's biggest drugs, and delays in resuming full-on production are making analysts nervous. By contrast, the Clolar setback isn't enormous. An analyst called it "an incremental negative." But it's a negative Genzyme didn't need.

- read the Reuters piece
- see the coverage from the Associated Press

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.